Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil

A 6-month, prospective, open-label study

Brian J Miller, Amy Claxton, Yangchun Du, Peter J. Weiden, Steven G. Potkin

Research output: Contribution to journalArticle

Abstract

We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.

Original languageEnglish (US)
Pages (from-to)44-48
Number of pages5
JournalSchizophrenia Research
Volume208
DOIs
StatePublished - Jun 1 2019

Fingerprint

Risperidone
Schizophrenia
Injections
Paliperidone Palmitate
aripiprazole lauroxil
Therapeutics

Keywords

  • Antipsychotic
  • Aripiprazole lauroxil
  • Long-acting injection
  • Paliperidone palmitate
  • Schizophrenia
  • Switching

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil : A 6-month, prospective, open-label study. / Miller, Brian J; Claxton, Amy; Du, Yangchun; Weiden, Peter J.; Potkin, Steven G.

In: Schizophrenia Research, Vol. 208, 01.06.2019, p. 44-48.

Research output: Contribution to journalArticle

@article{a2b4301f929d497b9290a30626307c19,
title = "Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study",
abstract = "We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30{\%} and 9{\%} over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.",
keywords = "Antipsychotic, Aripiprazole lauroxil, Long-acting injection, Paliperidone palmitate, Schizophrenia, Switching",
author = "Miller, {Brian J} and Amy Claxton and Yangchun Du and Weiden, {Peter J.} and Potkin, {Steven G.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.schres.2019.01.038",
language = "English (US)",
volume = "208",
pages = "44--48",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

TY - JOUR

T1 - Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil

T2 - A 6-month, prospective, open-label study

AU - Miller, Brian J

AU - Claxton, Amy

AU - Du, Yangchun

AU - Weiden, Peter J.

AU - Potkin, Steven G.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.

AB - We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.

KW - Antipsychotic

KW - Aripiprazole lauroxil

KW - Long-acting injection

KW - Paliperidone palmitate

KW - Schizophrenia

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=85061096805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061096805&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2019.01.038

DO - 10.1016/j.schres.2019.01.038

M3 - Article

VL - 208

SP - 44

EP - 48

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -